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Abstract
Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 oncoprotein, can
effectively target HER2-positive breast cancer through several mechanisms. Although the effects of trastuzumab on cancer
cell proliferation, angiogenesis and apoptosis have been investigated in depth, the effect of trastuzumab on microRNA
(miRNA) has not been extensively studied. We have performed miRNA microarray profiling before and after trastuzumab
treatment in SKBr3 and BT474 human breast cancer cells that overexpress HER2. We found that trastuzumab treatment of
SKBr3 cells significantly decreased five miRNAs and increased three others, whereas treatment of BT474 cells significantly
decreased two miRNAs and increased nine. The only change in miRNA expression observed in both cell lines following
trastuzumab treatment was upregulation of miRNA-194 (miR-194) that was further validated in vitro and in vivo. Forced
expression of miR-194 in breast cancer cells that overexpress HER2 produced no effect on apoptosis, modest inhibition of
proliferation, significant inhibition of cell migration/invasion in vitro and significant inhibition of xenograft growth in vivo.
Conversely, knockdown of miR-194 promoted cell migration. Increased miR-194 expression markedly reduced levels of the
cytoskeletal protein talin2 and specifically inhibited luciferase reporter activity of a talin2 wild-type 39-untranslated region,
but not that of a mutant reporter, indicating that talin2 is a direct downstream target of miR-194. Trastuzumab treatment
inhibited breast cancer cell migration and reduced talin2 expression in vitro and in vivo. Knockdown of talin2 inhibited cell
migration/invasion. Knockdown of trastuzumab-induced miR-194 expression with a miR-194 inhibitor compromised
trastuzumab-inhibited cell migration in HER2-overexpressing breast cancer cells. Consequently, trastuzumab treatment
upregulates miR-194 expression and may exert its cell migration-inhibitory effect through miR-194-mediated
downregulation of cytoskeleton protein talin2 in HER2-overexpressing human breast cancer cells.
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Introduction
HER2 is amplified and overexpressed in 25–30% of human
breast cancers. Treatment with trastuzumab (HerceptinH), a
humanized murine anti-HER2 monoclonal antibody [1], pro-
duced an objective response rate of 15% in extensively pretreated
patients [2] and in 26% of previously untreated women with
HER2-overexpressing metastatic breast cancer [3]. Trastuzumab
in combination with chemotherapy was significantly more effective
than chemotherapy alone in prolonging the time to disease
progression, duration of response and overall survival [4,5,6,7],
resulting in its approval by the FDA in 1998. Trastuzumab
provided one of the first deliberately targeted therapies for a
human cancer and has now become the first-line treatment of
choice for patients with primary or recurrent HER2-overexpress-
ing breast cancer [8].
Trastuzumab-based combination treatment with chemotherapy
are, however, effective in 60–70% of the HER2-overexpressing
breast cancers [7,9] and trastuzumab resistance often develops
during the course of treatment [9,10]. Improving response to
trastuzumab and reducing trastuzumab resistance is a critical and
urgent priority for improving the clinical management of a
substantial subset of patients with breast cancer. While significant
progress has been achieved, molecular mechanisms underlying the
action of trastuzumab are still not fully elucidated. Treatment with
trastuzumab inhibits proliferation of breast cancer cells by
blocking the phosphatidylinositol-3-kinase (PI3K) signaling path-
way, upregulating the cyclin dependent kinase inhibitor p27Kip1
and inducing G1 arrest of the cell cycle
[11,12,13,14,15,16,17,18,19,20]. We and others have also illus-
trated the ability of trastuzumab to interfere with DNA repair
[14,21] and tumor angiogenesis [22,23,24,25,26,27]. Others have
provided evidence that trastuzumab can cleave the extracellular
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domains of HER2 receptors [28,29], mediate antibody-dependent
cellular cytotoxicity [30,31,32], and can induce apoptosis
[33,34,35].
Despite these many observations, the effects of trastuzumab on
regulation of cellular processes by microRNA (miRNA) are still
not investigated in depth. miRNAs are small non-coding RNAs of
19–25 nucleotides that can negatively regulate gene expression at
post-transcriptional and transcriptional levels [36,37]. The binding
of miRNAs to complementary sites in the 39- untranslated regions
(UTRs) and other regions of protein-coding mRNA sequences
cause either degradation of the mRNA or inhibition of translation
[36,37]. miRNAs have been demonstrated to regulate many
normal physiological processes [36,37], to participate in malignant
transformation at many sites including breast cancer [38,39,40],
and to mediate sensitivity to chemotherapy and radiotherapy
[41,42,43]. In this report, we have measured the effect of
trastuzumab on miRNAs and the role of miRNAs in trastuzu-
mab-mediated regulation of human breast cancer cells that
overexpress HER2. We have found that treatment with trastuzu-
mab affected expression of several miRNAs. miR-194 was
upregulated and downregulated talin2, inhibited cell migration
and invasion, which may contribute to the anti-tumor activity of
trastuzumab on HER2-overexpressing breast cancer cells.
Materials and Methods
Cell lines and cell culture
Human breast cancer cell lines BT474, SKBr3, MDA-MB-361
and MDA-MB-231 were originally purchased from the American
Type Culture Collection (Manassas, VA) and stored, recovered
and used at early passage from cryopreservation in liquid nitrogen.
SKBr3, MDA-MB-361 and MDA-MB-231 cells were maintained
in RPMI 1640 medium containing 10% fetal bovine serum (FBS),
2 mM L-glutamine, penicillin (100 units/mL), and streptomycin
(100 mg/mL). BT474 cells were grown in complete medium
containing DMEM supplemented with 10% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate (Sigma, St. Louis, MO), 100
units/ml of penicillin, and 100 mg/ml streptomycin. All cell culture
media were obtained from the Media Preparation Core Facility at
the University of Texas MD Anderson Cancer Center. All cell
lines were cultured in a humidified air supplemented with
5% CO2 at 37uC and tested monthly for mycoplasma with a
MycoSensor PCR Assay Kit from Stratagene (Cat# 302109,
La Jolla, CA). All cell lines were authenticated by the Cell Line
Core Facility at the University of Texas MD Anderson Cancer
Center with short tandem repeat DNA fingerprinting in April,
2011.
Reagents
Trastuzumab (HerceptinH) manufactured by Genentech Inc
(South San Francisco, CA) was purchased from Division of
Pharmacy at the University of Texas MD Anderson Cancer
Center. Human immunoglobin G (hIgG) served as control for
trastuzumab and was purchased from Calbiochem (La Jolla, CA).
Antibodies reactive with vinculin and total Rb were purchased
from Cell Signaling Technology, Inc. (Beverly, MA). Antibody
against talin2 was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). miR-194 precursor and its miRNA negative
controls, miR-194 inhibitor and its negative inhibitor, and
TaqMan assay for miR-194 were purchased from Applied
Biosystems Incorporated (ABI, Foster City, CA). Small interfering
RNAs (siRNAs) targeted to talin2 and talin1 were from
Dharmacon (Lafayette, CO) or Ambion (Austin, TX). Epidermal
growth factor (EGF) used in cell culture was ordered from Sigma
(St. Louis, MO). Transfection reagents used were Lipofectamine
2000 from Invitrogen (Grand Island, NY) and DharmaFECT #4
from Dharmacon.
Preparation of Total RNA
Total RNA was extracted with the TRIzol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. RNA
purity was assessed by measuring absorption at 260 nm (A260)
and at 280 nm (A280) (samples that had A260/A280 ratio of 1.9–
2.1 were considered acceptable) and by ethidium bromide staining
of 18S and 28S RNA on gels after electrophoresis. RNA
concentrations were determined from the A260. Before perform-
ing the microRNA assay, each RNA sample was treated by DNase
with a Turbo DNase kit (Ambion, Austin, TX).
miRNA Microarray Profiling
miRNA profiling was performed in the non-coding RNA core
facility at M.D, Anderson Cancer Center. Briefly, 5 mg of RNA
from each tissue sample was labeled with biotin by reverse
transcription using random octomers in duplicate. Hybridization
was carried out on the second version of a miRNA-chip A-MEXP-
1246 version (http://www.ebi.ac.uk/arrayexpress/arrays/A-
MEXP-1246), which contained 559 human and 393 mouse
miRNA probes, 962 human ultraconserved sequences in quadru-
plicate. Each oligo was printed in duplicate in two different slide
locations. Hybridization signals were detected by biotin binding of
a Streptavidin-Alexa647 conjugate (one-color signal) using a
GenePix 4000B scanner (Axon Instruments). We quantified
images using the GenePix Pro 6.0 (Axon Instruments). Raw data
were analyzed in BRB-ArrayTools developed by R. Simon and
A.P. Lam (version: 4.2.1, National Cancer Institute). Expression
data were normalized by quantiles method of the Bioconductor
package. Statistical comparisons were done using BRB class
comparison t-test. A total of 16 samples from BT474 cells (8 from
wild-type or trastuzumab-sensitive cells and another 8 from
trastuzumab-resistant cells) and 8 samples from SKBr3 cells (4
from wild-type or trastuzumab-sensitive cells and another 4 from
trastuzumab-resistant cells) were analyzed. Samples were discard-
ed if more than 87.5% and 75% for BT474 and SKBr3 cell line,
respectively, of missed values occurred (the miRNAs are retained
when present in at least the smallest group in the dataset), missed
values were replaced with 4.500001 (basic expression value, log2)
after normalization. miRNAs significant at 0.05 level of the
univariate test were reported. This microRNA microarray data
regarding breast cancer cell lines treated with or without
trastuzumab have been deposited into the ArrayExpress (http://
www.ebi.ac.uk/miamexpress/).
Quantitative Reverse Transcription–Polymerase Chain
Reaction (QRT-PCR) Analysis
QRT-PCR was performed to assess mir-194 levels with the use
of a Prism 7900HT Sequence Detection System (ABI, Foster City,
CA) and TaqMan Real-Time PCR Assay (ABI). Total RNA was
reversely transcribed into complementary DNA (cDNA) with
specific stem-loop RT primer and a cDNA kit from ABI. Hsa-
miR-194 was purchased from ABI (Assay ID 000493). Amplifi-
cations were carried out in triplicate on MicroAmp optical 96-well
microliter plates (ABI). Thermal cycling conditions were as follows:
95uC for 5 minutes, followed by 40 cycles of 95uC for 10 seconds
and 59uC for 40 seconds. U6 RNA was used as an internal control
in all QRT-PCR assays for miRNA. The DDCT method was used
to compare the relative expression levels between treatments. The
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final PCR results were expressed as the relative expression
compared to individual control sample in each assay.
RNA Blotting
miR-194 Northern blotting was performed as described
previously [44]. Briefly, total RNA isolation was performed using
the Tri-Reagent (Invitrogen). RNA samples of 25 mg each were
run on 15% acrylamide denaturing (urea) criterion precast gels
(Bio-Rad), and then transferred onto Hybond-N_membrane
(Amersham Pharmacia Biotech). The hybridization with a DNA
oligonucleotide probe complementary to the mature miR-194
sequence end-labeled with [c-32P] ATP was performed at 42uC in
7% SDS/0.2 M Na2PO4 (pH 7.0) overnight. The membrane was
washed twice at 42uC with 26 standard saline phosphate EDTA
(SSPE, 0.18 M NaCl/10 mM phosphate, pH 7.4/1 mM EDTA)/
0.1% SD S and twice with 0.56 SSPE/0.1% SDS. The blot was
stripped by boiling in 0.1% SDS/0.16 SSC for 10 min and was
reprobed U6 snRNA as a loading control.
miRNA Transfection
BT474 or SKBr3 cells were seeded on 6-well culture plates and
transfected with a negative control sequence or miR-194 using the
DF4 reagent (Dharmacon). The mixture of miRNA (15 nM final
concentration) and DF4 reagent (12.5 nM final concentration)
were incubated for 20 min before being added to cells. Transfec-
tion was carried out for 72 hrs and cells were harvested for
extraction of RNA or protein.
Cell Proliferation Assays
A crystal violet cell proliferation assay was used to assess
anchorage-dependent cell proliferation as described previously
[15]. Briefly, BT474 stable cells that either express empty vector or
miR-194 were seeded and cultured in triplicate in 96-well cell
culture plates for different intervals. The cells were washed with
phosphate-buffered saline, fixed in 1% glutaraldehyde, and stained
with 0.5% crystal violet (Sigma Chemical Co.) dissolved in
methanol. The dye that stained the cells on the plates was then
eluted with Sorenson’s buffer (0.9% sodium citrate, 0.02 N HCl,
and 45% ethanol), and directly measured with the use of a Vmax
microplater reader (Molecular Devices, Sunnyvale, CA) at a
wavelength of 560 nm. Cell number was expressed as the optical
density (OD) at 560 nm.
BT474 Human Breast Cancer Xenografts in Nude Mice
The BT474 xenograft model was established in female nu/nu
Balb/c mice as described previously [22] . Briefly, BT474 wild-
type cells or stable transfectants expressing miR-194 were injected
subcutaneously into two mammary fat pads of 4-week-old BALB/
c athymic Nu/Nu mice (obtained from the in-house animal facility
at the Department of Experimental Radiation Oncology, the
University of Texas MD Anderson Cancer Center). Experiments
with nu/nu mice were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of Texas MD
Anderson Cancer Center. All mice were maintained under specific
pathogen-free conditions and given sterile food and water. Once
the tumors became palpable (at day 14 after injection), the mice
were randomly divided into two treatment groups (6 mice per
group): 1) intraperitoneal injection with control hIgG (1 mg/kg)
twice a week for 3 weeks.; or 2) intraperitoneal injection with
trastuzumab (1 mg/kg) twice a week for 3 weeks. At the end of
treatment, all tumors were collected and weighed. A portion of the
xenografts was used for RNA and protein isolation; another
portion was fixed in formalin and embedded in paraffin; and third
portion was frozen in liquid nitrogen. Experiments with nude mice
were repeated twice with similar results.
miR-194 Expression Construct
A miR-194 core fragment was amplified from BT474 genomic
DNA by using the following primer set: CTAAGCTTAGTGGG-
CATGGGACACTCT (miR-194-2F) & CTGAATT-
CACCTGCCTCTCCTTCTTCGT (miR-194-2R) and sub-
cloned into pEGPF-C1 vector digested with HindIII and EcoRI.
The sequence of this miR-194 construct was verified by direct
sequencing and QRT-PCR after transient expression.
Generation of Trastuzumab-resistant Cells and Stable
Clones that Express miR-194 in BT474 and SKBr3 cells
Trastuzumab-resistant SKBr3 and BT474 cells were generated
as reported previously [45]. Two stable clones that express miR-
194 and two control clones that express the backbone vector
(pEGPF-C1) were established in BT474 cells using previously
reported methods [46] .
Generation of 39 UTR reporter constructs of talin2
Prediction of miR-194 binding sites was performed using
TargetScan software (http://www.targetscan.org/). A fragment of
39-9UTR region of the talin2 contains the predicted binding site
for miR-194 and was amplified by PCR using the primers:
TCTAGAGGCTGCATGATCGTGATGT (forward) and
TCTAGATCATAAAGAGGTCCAGGAGCA (reverse), which
contained Xba I restriction sites (underlined nucleotides). The
PCR product was purified, digested and cloned into pGL3 vector
(Promega, Madison, WI) via the Xba I site, which is located
downstream of the firefly luciferase reporter gene. QuikChangeH
II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA) was used to generate a deletion mutation in the miR-
194 seed region according to the manufacturer’s instructions.
Following mutagenic primers: 59-GGGTGCACGTTTCATG-
GACAACAAAGAAAAGTCAGT-39 (deletion sense) and 59-
ACTGACTTTTCTTTGTTGTCCATGAAACGTGCACCC-
39 (deletion antisense) were utilized. Generated constructs were
confirmed by direct sequencing using an ABI 3730xl DNA
sequencer at the DNA Analysis Core Facility at the University of
Texas MD Anderson Cancer Center.
Dual Luciferase Reporter Assay
Luciferase activity assays were performed as previously reported
[46] . Briefly, cells were seeded in 6-well plates, cotransfected with
miR-194 precursor or its negative control and a wild-type or
mutated talin2 39-UTR reporter construct as described above. A
Renilla luciferase vector (pRL-TK) served as an internal control
and was included in all samples. After transfection for 16 hrs, cells
were split into 12-well plates, harvested after 24 hrs and Firefly
and Renilla luciferase activities were measured sequentially using
the dual luciferase assay kit (Promega) and a luminometer. Results
were expressed as relative luciferase activity after normalization
with Renilla luciferase activity. Results represent three independent
experiments and each performed in triplicate.
Immunoblot Analysis
Total cell lysates were prepared and Western blotting was
performed as described previously [15]. Briefly, cells were
transfected with miR-194 precursors for 3 days, and then
harvested for total lysate preparation. Total lysates were separated
on 6% SDS-polyacrylamide gel and blotted onto nitrocellulose
membrane. The membrane was incubated with horseradish
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peroxidase–conjugated secondary antibody (1:2000; GE health-
care) and bound antibody was visualized with the use of a
SuperSignal West Dura chemiluminescent kit (Thermo Fisher,
Rockford, IL).
Flow Cytometry
The percentage of the sub-G1 cell population (apoptotic cells)
and the cell cycle distribution were determined based on relative
DNA content with the use of flow cytometry as described
previously [15].
Cell Migration Assay
26105 of BT474 cells or 56104 SKBr3 cells in 0.5 ml of serum-
free medium were introduced into the upper compartment of the
BD BioCoat control inserts (Cat. # 354578, BD Discovery
Labware, Bedford, MA) fitted with membranes of 8 micron
porosity separating the upper and lower compartments. The lower
compartment was filled with normal culture medium, medium
supplemented with 10% FBS. After 16 hrs of incubation, cells
were wiped off from the upper surface of each insert. The cells on
the lower surface, which represented the cells that migrated
through control insert membrance, were fixed and stained with
Diff-Quick (Siemens, Deerfield, IL) and counted by microscopic
examination in 10 representative fields. Cell migration was
expressed as relative migration relative to the migration of each
control group. Cell migration at each control group was arbitrarily
set as 1. Each condition was assayed in triplicate and each
experiment was repeated at least three times.
Cell Invasion Assay
Invasion assays were performed using BD Biocoat Matrigel
Invasion Chambers (Cat. # 354480, BD Discovery Labware,
Bedford, MA) that contain an 8 micron pore size PET membrane
with a thin layer of MATRIGEL Basement Membrane Matrix by
following the manufacturer instructions. Briefly, control-treated or
miR-194 (or trastuzumab)-treated BT474 or SKBr3 cells were
introduced into the upper compartment, incubated for 24 hrs,
fixed and stained after removing non-invading cells as described
above for the Cell Migration Assay. Cell invasion is then
calculated as the percent invasion through the matrigel matrix
and membrane relative the migration through the control
membrane. Cell invasion at each control group was arbitrarily
set as 1. Cell invasion data was expressed as relative invasion
relative to the invasion of control group.
In Vitro Scratch Assay
BT474 (56106 cells/well) or SKBr3 (26106 cells/well) cells
were seeded to 90% confluence in a 6-well plate for overnight
culture. The following day a scratch was made through the center
of each well using a 200-mL pipette tip, creating an open ‘‘scratch’’
or ‘‘wound’’ that was clear of cells. The dislodged cells were
removed by three washes with complete culture media, and cells
were incubated under standard conditions. Migration into the
open area was documented at 72 hrs post-scratching.
Vinculin Immunofluorescence (IF) Staining
SKBr3 cells were seeded at 1.56105 cells onto collagen (10 mg/
ml) and poly-L-lysine (1 mg/ml) coated glass coverslips in 6-well
dishes. Cells were grown for 16 hrs and then either cultured
untreated or treated with control hIgG (10 mg/ml) or trastuzumab
(10 mg/ml) for 16 hrs. Cells were fixed in ice-cold MeOH at
220uC for 5 min. Fixed cells were permeabilized and immuno-
stained with rabbit anti-vinculin and followed by incubation with
secondary antibody secondary antibody conjugated with Alexa
Fluor 594 (Invitrogen). Coverslips were mounted on glass slides
and examined using an Olympus FluoView FV1000 confocal
microscope (Center Valley, PA).
Ethics Statement
All animal experiments with nu/nu mice were reviewed and
approved by the Institutional Animal Care and Use Committee at
the University of Texas MD Anderson Cancer Center. Animals
were euthanized when the mice became morbid or the tumor size
is 1.5 cm in the largest diameter.
Statistical Analysis
All experiments were repeated at least three times on different
occasions. The results are presented as the mean 6 SD for all
values. A paired Student’s t test was used to evaluate statistically
significant differences in miR-194 levels between the treatment
groups and the vehicle control group. P,0.05 was considered
statistically significant. All statistical tests and corresponding P
values were two-sided.
Results
Trastuzumab treatment upreguates miR-194 in HER2
overexpressing breast cancer cells
To determine the effects of trastuzumab treatment on miRNAs
in HER2-overexpressing breast cancer cells, SKBr3 and BT474
cells were treated with trastuzumab or control hIgG. RNA was
extracted and profiled on a miRNA chip (ArrayExpress) that
contained 559 human miRNA probes and 962 human ultra-
conserved sequences. Raw data were analyzed using a GeneSpring
GX 7.3. The filter on fold change was set at 1.2 since this
threshold had been demonstrated to reflect a significant biological
difference [47]. As shown in Table 1, trastuzumab treatment in
SKBr3 cells increased 23 human miRNAs including miR-194 and
miR-629, but decreased 33 human miRNAs in SKBr3 cells. In
BT474 cells, trastuzumab treatment upregulated more miRNAs
than it downregulated. As shown in Table 2, trastuzumab
increased 40 human miRNAs including miR-194, decreased 18
human miRNAs in BT474 cells. To visualize the clusters of the
differentially expressed miRNAs in response to trastuzumab
treatment in the two cell lines, hierarchical clustering was
performed using one minus correlation as a distance measure
and average linkage method for defining the distance between the
clusters (Fig. S1). When miRNA changes were compared in
SKBr3 and BT474 breast cancer cells, miR-194 upregulation was
the only change shared by both cell lines. Consequently, miR-194
was selected for further study.
Trastuzumab upreguates miR-194 in cell culture and in
xenografts
To confirm that miR-194 was upregulated by trastuzumab
(Tables 1 & 2), total RNA was extracted from trastuzumab-treated
SKBr3 and BT474 cells in culture and subjected to quantitative
reverse-transcription PCR (QRT-PCR) and Northern blot anal-
yses. QRT-PCR analysis confirmed that trastuzumab treatment
increased miR-194 by 1.64 fold in SKBr3 cells (Fig. 1A) and by
1.95 fold in BT474 cells (Fig. 1A). Northern blotting further
confirmed that trastuzumab treatment increased miR-194 level by
2.1 fold in BT474 cells (Fig. 1C). An assay with a miR-194-specific
sensor reporter also indicated that trastuzumab increased miR-194
expression (data not shown). Consistent with above results in cell
culture, QRT-PCR analysis of BT474 xenograft tumor samples
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Table 1. miRNAs affected by trastuzumab in SKBr3 cells.
Unique ID
Mean ratio of
trastuzumab vs
control hlgG
p-value
(t-test)
Geom mean of intensities in
SKBr3 cells treated with
control hIgG for 20 hrs
(BRC20)
Geom mean of intensities
in SKBr3 cells treated with
trastuzumab for 20 hrs
(BRHCT20)
hsa-mir-548b-A 0.065146674 0.0002274 347.37 22.63
hsa-mir-551a-P 0.071772555 0.0185408 452.68 32.49
hsa-mir-624-A 0.072392834 0.0169737 312.6 22.63
hsa-mir-648-A 0.075340413 0.0148338 300.37 22.63
hsa-mir-544-A 0.076597617 1.10E-05 295.44 22.63
hsa-mir-26a-2-P 0.083364032 0.0067642 271.46 22.63
hsa-mir-508-A 0.086219377 0.0030508 262.47 22.63
hsa-mir-608-P 0.099895462 0.028476 325.24 32.49
hsa-mir-33-A 0.100908274 0.0283768 300.57 30.33
hsa-mir-519a1-5p/526c-A 0.103456158 2.57E-05 218.74 22.63
hsa-mir-433-P 0.103754986 0.0014047 218.11 22.63
hsa-mir-548a3-P 0.110535828 0.033025 204.73 22.63
hsa-mir-516-4-5p-A 0.116595394 0.0157548 194.09 22.63
hsa-mir-520g-P 0.132984662 0.01343 170.17 22.63
hsa-mir-526a-2-P 0.135202744 0.0372519 247.85 33.51
hsa-mir-192-P 0.174889247 0.0003376 397.28 69.48
hsa-mir-519b-3p/526c-A 0.180074799 0.0152054 125.67 22.63
hsa-mir-141-P 0.202469357 0.0036423 111.77 22.63
hsa-mir-153-2-A 0.215605945 0.0208085 104.96 22.63
hsa-mir-381-A 0.240514401 0.0338008 94.09 22.63
hsa-mir-613-P 0.264091493 0.0242617 85.69 22.63
hsa-mir-135b-A 0.277634646 0.0053856 81.51 22.63
hsa-mir-506-P 0.314426262 0.0432334 199.22 62.64
hsa-mir-616-P 0.362195903 0.0017904 62.48 22.63
hsa-mir-651-A 0.381449112 0.0349512 212.82 81.18
hsa-mir-496-P 0.410558781 0.0179086 55.12 22.63
hsa-mir-652-A 0.45070703 0.045327 50.21 22.63
hsa-mir-624-P 0.477062244 0.0097793 139.29 66.45
hsa-mir-200a*-5p-A 0.509914376 0.0301038 44.38 22.63
hsa-mir-135a-1-A 0.558314088 0.0331035 103.92 58.02
hsa-mir-196b-P 0.56347169 0.0475296 2699.55 1521.12
hsa-mir-214-A 0.697566648 0.0485026 1745.74 1217.77
hsa-mir-29a-A 0.713695323 0.0199925 1379.23 984.35
hsa-mir-629-A 1.215502868 0.0165149 1799.28 2187.03
hsa-mir-194-2-A 1.222424312 0.0168992 3056.95 3736.89
hsa-mir-27b-A 1.466522781 0.0174398 838.63 1229.87
hsa-mir-572-P 1.710230649 0.0482883 706.7 1208.62
hsa-mir-518a2-5p/mir527-A 2.068051259 0.0064793 22.63 46.8
hsa-mir-569-P 2.840919134 0.0007198 22.63 64.29
hsa-mir-17-3p-A 2.933274414 0.0304101 22.63 66.38
hsa-mir-431-A 3.683163942 0.0495408 22.63 83.35
hsa-mir-30d-P 3.899322034 0.0487109 29.5 115.03
hsa-mir-96-P 4.094521778 0.022245 44.54 182.37
hsa-mir-557-P 4.207247017 0.0134777 22.63 95.21
hsa-mir-105-2-A 4.314184711 ,1e-07 22.63 97.63
hsa-mir-489-P 4.814453843 0.0087891 54.38 261.81
hsa-mir-505-P 5.205695142 0.0310113 29.85 155.39
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also showed that treatment with trastuzumab induced miR-194
expression by 3.1 fold compared to control hIgG (Fig. 1D).
Collectively, above results confirm that trastuzumab induces miR-
194 in cell culture and in vivo.
Trastuzumab specifically induces miR-194 expression in
trastuzumab-sensitive breast cancer cells
As shown in Figure 1E, miR-194 expression increased only in
trastuzumab-sensitive SKBr3 and BT474 parental cells but not in
trastuzumab-resistant cells. Additionally, miR-194 was not in-
duced by trastuzumab treatment in either the MDA-MB-231
breast cancer cell line that expresses low levels of HER2 and is
insensitive to trastuzumab or the KPL4 breast cancer cell line that
expresses high levels of HER2 and is insensitive to trastuzumab
(Fig. S2). Thus, miR-194 is specifically induced by trastuzumab
treatment and may associate with trastuzumab response.
Increased expression of miR-194 significantly inhibits
migration and invasion of breast cancer cells that
overexpress HER2
We next explored the biological function of miR-194 in breast
cancer. Two approaches were used to study the function of miR-
194 in breast cancer cells: transient and stable expression of miR-
194 in BT474 or SKBr3 breast cancer cells. The effects of
transient and stable expression of miR-194 on cell viability, cell
cycle, apoptosis and cell migration/invasion were evaluated.
Stable expression of miR-194 in subclones of BT474 cells was
confirmed with QRT-PCR and shown in Figure 2A. As shown in
Figure 2B, stable overexpression of miR-194 in two BT474 stable
clones (#22 and #23) produced moderate inhibition of cell
growth as measured with a crystal violet viability assay. No
significant change in cell cycle distribution or apoptosis was
observed in subclones of BT474 with stable overexpression of
miR194 (data not shown). Transient overexpression of miR-194
significantly decreased the ability of SKBr3 cells to migrate
(Fig. 2C). Compared with the negative control miRNA, miR-194
expression reduced SKBr3 cell migration by 56% (Fig. 2D).
Transient overexpression of miR-194 also decreased the ability of
SKBr3 cells to detach from and invade through the matrigel
matrix as illustrated in the cell invasion assay (Fig. 2E). Validation
of miR-194 transient expression was performed with QRT-PCR
and shown in Figure 2F. Additionally, stable overexpression of
miR-194 inhibited the ability of BT474 cells to migrate by 40%
and to invade by 55% (Fig. 2G & 2H). The effect of miR-194 on
HER2-overexpressing breast cancer cells was further evaluated in
a BT474 xenograft model. As shown in Figure 2I, miR-194
expressing BT474 tumors grew significantly less rapidly than did
tumors containing breast cancer cells with an empty vector. Taken
together, these data indicate that miR-194 can significantly inhibit
cell migration/invasion in vitro, and tumor growth in vivo in
breast cancer cells that overexpress HER2.
miR-194 directly targets the talin2 gene and
downregulates talin2 protein
We next asked whether miR-194 targeted the expression of
proteins which regulate migration and invasion of breast cancer
cells (Fig. 2). Based on the UCSC genome database at http://
genome.ucsc.edu/, miR-194-2 maps on human chromosome 11
within an intron of an unknown human gene (AB429224, also
called Homo sapiens cDNA FLJ35483). Using the TargetScan and
miRanda programs, we identified talin2 that encodes a cytoskel-
etal protein as one of many genes targeted by miR-194. The
putative miR-194 target site in the 39-UTR of talin2 gene shows a
close match to nucleotides 2 to 18 of miR-194 (Fig. 3A). The miR-
194 target site is also highly conserved among multiple species
including humans, chimpanzees, mice, rats, rabbits, hedgehogs,
dogs, cats, horses and elephants (Fig. 3A). To determine whether
miR-194 acts directly on talin2 39-UTR, we conducted luciferase
reporter assays, cotransfecting miR-194 and luciferase reporter
constructs containing wild type (underlined letter in Figure 3A) or
mutant (deletion of underlined letter in Figure 3A) talin2 39-UTR.
Luciferase activity was dramatically decreased by approximately
60% in the presence of miR-194 when compared with its negative
miRNA control (Fig. 3B). In contrast, miR-194 did not alter
activity of the mutant talin2 luciferase reporter that contained the
deletion of miR-194 binding site (Fig. 3B), indicating miR-194
specifically act on wild-type talin2 39-UTR. In agreement with the
luciferase reporter results, transient overexpression of miR-194
significantly decreased talin2 protein expression (Fig. 3C). These
data indicate that talin2 is a direct target of miR-194 in breast
cancer cells.
Depletion of talin2 inhibits cell migration and invasion in
breast cancer cells that overexpress HER2
We next asked whether talin2 regulates cell migration and
invasion. Both talin1 and talin2 encode high-molecular-weight
Table 1. Cont.
Unique ID
Mean ratio of
trastuzumab vs
control hlgG
p-value
(t-test)
Geom mean of intensities in
SKBr3 cells treated with
control hIgG for 20 hrs
(BRC20)
Geom mean of intensities
in SKBr3 cells treated with
trastuzumab for 20 hrs
(BRHCT20)
hsa-mir-583-A 5.604502889 0.0038414 50.19 281.29
hsa-mir-640-P 6.07512152 6.07E-05 22.63 137.48
hsa-mir-548d1-A 8.575879397 0.0167225 29.85 255.99
hsa-mir-519a1-3p-A 9.625276182 4.25E-05 22.63 217.82
hsa-mir-605-A 11.04639859 0.0011691 22.63 249.98
hsa-mir-340-P 11.06934673 0.0302754 29.85 330.42
hsa-mir-198-A 11.44410075 0.0041912 22.63 258.98
hsa-mir-19b2-A 12.41228458 0.0020803 22.63 280.89
hsa-mir-518e-3p-A 13.12019443 0.002743 22.63 296.91
doi:10.1371/journal.pone.0041170.t001
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Table 2. miRNAs affected by trastuzumab in BT474 cells.
Unique ID
Mean ratio of
trastuzumab vs
control hlgG
p-value
(t-test)
Geom mean of intensities in
BT474 cells treated with
control hIgG for 48 hrs
(BTC48)
Geom mean of intensities in BT474
cells treated with trastuzumab for
48 hrs (BTHCT48)
hsa-mir-211-P 0.092615377 0.034884 382.01 35.38
hsa-mir-514-2&3-A 0.10147527 0.000624 223.01 22.63
hsa-mir-518e-5p/526c-A 0.116523351 0.019672 194.21 22.63
hsa-mir-452*-3p-A 0.116631449 0.034182 194.03 22.63
hsa-mir-518a2-5p/mir527-A 0.144231995 0.035946 156.9 22.63
hsa-mir-524*-5p-A 0.162257116 0.00944 139.47 22.63
hsa-mir-518b-A 0.173503028 0.012805 130.43 22.63
hsa-mir-105-2-P 0.209385572 0.012188 458.15 95.93
hsa-mir-520h-P 0.227391479 0.002751 99.52 22.63
hsa-mir-519e*-5p-A 0.242584266 0.002037 331.39 80.39
hsa-mir-646-A 0.242915414 0.023069 93.16 22.63
hsa-let-7g-P 0.257715522 5.90E-06 87.81 22.63
hsa-mir-323-A 0.291360886 0.002132 77.67 22.63
hsa-mir-517b-3p-A 0.291698891 0.009441 77.58 22.63
hsa-mir-432-5p-A 0.292150788 0.010767 77.46 22.63
hsa-mir-515-1-5p-A 0.305356902 7.16E-05 74.11 22.63
hsa-mir-548a1-A 0.500150716 0.017816 663.5 331.85
hsa-mir-671-A 0.780467508 0.030883 1862.64 1453.73
hsa-mir-758-P 1.203505577 0.010282 790.74 951.66
hsa-mir-485-3p-A 1.226628339 0.007659 1019.29 1250.29
hsa-mir-102-A 1.238857151 0.007481 1353.11 1676.31
hsa-mir-202-3p-A 1.29220961 0.03779 964.65 1246.53
hsa-mir-629-A 1.363440315 0.017991 2721.96 3711.23
hsa-mir-663-P 1.371448683 0.003362 1647.98 2260.12
hsa-mir-560-P 1.446595051 0.041021 831.29 1202.54
hsa-mir-296-A 1.45630605 0.010238 545.27 794.08
hsa-mir-324-5p-A 1.462267846 0.032113 1455.39 2128.17
hsa-mir-219-1-P 1.517478105 0.000529 17165.19 26047.8
hsa-mir-206-P 1.594267196 0.000415 577.03 919.94
hsa-mir-498-A 1.630858004 0.019047 783.33 1277.5
hsa-mir-19b2-A 1.699504866 0.038757 351.42 597.24
hsa-mir-194-2-A 1.828481053 0.00689 3749.44 6855.78
hsa-mir-219-2-P 1.868439905 0.008312 1298.19 2425.59
hsa-mir-429-P 1.895429772 0.031979 1099.07 2083.21
hsa-mir-564-P 2.086289374 0.018767 875.89 1827.36
hsa-mir-521-2-P 2.461776403 0.010133 22.63 55.71
hsa-mir-126-5p-A 2.653743792 0.002951 1067.1 2831.81
hsa-mir-199a*-3p-A 2.856385329 0.048539 22.63 64.64
hsa-mir-101-1/2-P 3.303137428 0.000142 22.63 74.75
hsa-mir-638-P 3.462660186 0.04302 22.63 78.36
hsa-mir-548a3-P 3.467962881 0.000185 22.63 78.48
hsa-mir-571-A 3.785682722 0.000292 22.63 85.67
hsa-mir-643-P 3.855501547 1.14E-05 22.63 87.25
hsa-mir-662-P 4.589482987 0.009066 22.63 103.86
hsa-mir-559-P 4.655766681 7.55E-05 22.63 105.36
hsa-mir-584-A 5.155103844 0.030886 22.63 116.66
hsa-mir-585-P 6.66195316 0.018554 22.63 150.76
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Table 2. Cont.
Unique ID
Mean ratio of
trastuzumab vs
control hlgG
p-value
(t-test)
Geom mean of intensities in
BT474 cells treated with
control hIgG for 48 hrs
(BTC48)
Geom mean of intensities in BT474
cells treated with trastuzumab for
48 hrs (BTHCT48)
hsa-mir-659-A 6.761655012 0.015715 85.8 580.15
hsa-mir-587-A 7.121078215 0.019825 22.63 161.15
hsa-mir-591-A 8.88054883 0.048778 37.17 330.09
hsa-mir-18b-P 8.956212523 0.023338 71.71 642.25
hsa-mir-152-A 13.43314501 0.036953 37.17 499.31
hsa-mir-642-P 17.71718957 0.006654 22.63 400.94
hsa-mir-21-P 17.86831639 0.004662 22.63 404.36
hsa-mir-567-P 22.46221829 0.007096 22.63 508.32
hsa-mir-337-A 24.40212108 0.008015 22.63 552.22
hsa-mir-652-A 27.14891737 2.90E-05 22.63 614.38
hsa-mir-136-A 32.47459125 0.005502 22.63 734.9
doi:10.1371/journal.pone.0041170.t002
Figure 1. Trastuzumab upregulates miR-194 expression in vitro and in vivo. HER2-overexpressing breast cancer cell lines BT474 (A) and
SKBr3 (B) were treated with trastuzumab (Tras) or control hIgG (10 mg/ml) for 48 hrs. Total RNA was prepared and analyzed by QRT-PCR to measure
miR-194. * p,0.05 compared to hIgG control. (C) Northern blot analysis of miR-194 expression. BT474 cells were treated with Tras or control hIgG
(10 mg/ml) for 48 hrs. Total RNA was prepared and analyzed by Northern blotting to detect miR-194. U6 non-coding small nuclear RNA (snRNA)
served as a loading control. (D) QRT-PCR quantitation of miR-194 expression in vivo. BT474 xenografts in miR-194 levels were measured by QRT-PCR.
* p,0.05 compared to hIgG control. (E) QRT-PCR quantitation of miR-194 expression in trastuzumab sensitive or resistant cell lines. Parental SKBr3
and BT474 (trastuzumab-sensitive), and their derived resistant cells were treated with Tras or control hIgG for 48 hrs. Total RNA was prepared and
analyzed by QRT-PCR to detect miR-194. * p,0.05 compared to hIgG control.
doi:10.1371/journal.pone.0041170.g001
Trastuzumab and miR-194-Talin2-Migration Pathway
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e41170
cytoskeletal proteins that concentrate in focal adhesions and link
integrins to vinculin and actin [48,49]. To study the role of talin2
in cell migration, SKBr3 cells were transiently transfected with two
siRNAs targeting talin2 or a negative control siRNA, and cell
migration and invasion were assayed as described in Material and
Methods. As shown in Figure 3D, knockdown of talin2 signifi-
cantly inhibited migration of SKBr3 cells compared to the control
siRNA. Talin2 silencing decreased cell invasion capacity as well
(Fig. 3E). Two siRNAs used to downregulate talin2 was confirmed
with Western blotting and shown in Figure 3F. Above data
indicate that talin2 silencing decreases cell migration and invasion
of SKBr3 cells.
Trastuzumab treatment inhibits cell migration and
disrupts the normal vinculin staining pattern in breast
cancer cells that overexpress HER2
While the effects of trastuzumab on cancer cell proliferation,
angiogenesis, and apoptosis have been investigated in depth, the
effect of trastuzumab on cell migration has received less attention.
Both BT474 and SKBr3 cells respond to trastuzumab treatment,
but are not actively motile. Long intervals are required to measure
cell migration assay or to observe healing of scratches in cancer
cell monolayers. Treatment of BT474 and SKBr3 with trastuzu-
mab for 3 days significantly inhibited the ability of both cell lines to
heal scratch assays (Fig. 4A). To study the effect of trastuzumab on
cell migration over a shorter interval (16 h) and to minimize the
effect of cell proliferation on scratch assays, we have stimulated
SKBr3 cell migration with epidermal growth factor (EGF) and
found that motility of trastuzumab-treated cells was significantly
slower than that of hIgG-treated controls (Fig. 4B). Stimulation of
SKBr3 cells with EGF for 16 hrs had no effect on miR-194
expression (data not shown). Similar results were observed in
transwell cell migration assays (see below).
Treatment with trastuzumab disrupts cytosekeltal
organization
SKBr3 cells were treated with trastuzumab and stained by
immunofluorescence for expression of vinculin, a cytoskeletal
protein associated closely with talin2 and exhibiting a similar
subcellular distribution [49]. In the absence of a specific antibody
for talin2 for immunofluorescence studies, we have used the
Figure 2. Increased miR-194 expression inhibits breast cancer cell migration and invasion. (A) miR-194 expression in the stable clones of
BT474 cells. BT474 cells were stably transfected with an empty pEGFP-C1 vector or pEGFP-miR-194 vector under the selection of G418. Two control
clones #17 and #19 that contain empty vector and two miR-194-expressing clones #22 and #23 were established and subjected for QRT-PCR
analysis. Hsa-miR-194 was purchased from ABI (Assay ID 000493). (B) Cell viability assay of BT474 stable cells that express miR-194 or its control
vector. BT474 cells were stably transfected with empty pEGFP-C1 vector or pEGFP-miR194 construct under the selection of G418. Two control clones
#17 and #19 that contain empty vector and two miR-194-expressing clones #22 and #23 were chosen to measure viability of crystal violet-stained
cells on day 1, day 3 and day 5. (C) Effect of miR-194 precursor on cell migration in SKBr3 cells. SKBr3 cells were transiently transfected with a miR-194
precursor or a control miRNA (miR CTRL) for 48 hrs and motility was measured overnight in a Transwell assay. (D) Quantitation of the SKBr3 cell
migration as shown in (C). * p,0.05 compared to miR control. (E) Effect of miR-194 precursor on cell invasion in SKBr3 cells. SKBr3 cells were
transiently transfected with a miR-194 precursor or a control miRNA (miR CTRL) for 48 hrs and invasion measured overnight. * p,0.05 compared to
miR control. (F) miR-194 expression in transiently transfected SKBr3 cells. SKBr3 cells were transiently transfected with a miR-194 precursor or a
control miRNA (miR CTRL) for 48 hrs. Total RNA was extracted and subjected to QRT-PCR analysis for miR-194 expression. Hsa-miR-194 was purchased
from ABI (Assay ID 000493). (G) Assay of cell migration in BT474 stable cells that express miR-194 or a control vector. The control clone #17 and the
miR-194-expressing clone #22 were chosen to study migration. * p,0.05 compared to #17 control. (H) Cell invasion assay in BT474 stable cells that
express miR-194 or its control vector. The control clone #17 and the miR-194-expressing clone #22 were chosen to study invasion. * p,0.05
compared to#17 control. (I) BT474 xenograft tumor growth in vivo. BT474 xenografts in nude mice were established with the control clone#17 and
the miR-194-expressing clone #22 as described in Methods. Tumors were collected and weighed after 4 weeks. * p,0.05 compared to #17 control.
doi:10.1371/journal.pone.0041170.g002
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behavior of vinculin as a surrogate for talin2. As shown in
Figure 4C, trastuzumab treatment for 16 hrs altered the staining
pattern of vinculin. Instead of well ordered, discrete and focal
staining of vinculin on the cell periphery, trastuzumab treatment
produced disordered and clumpy staining both in the cytoplasm
and at the cell’s periphery. These observations suggest that
trastuzumab can inhibit migration and disrupt the normal
distribution of cytoskeletal proteins in breast cancer cells that
overexpress HER2.
Trastuzumab treatment downregulates talin2 protein
expression in vitro and in vivo in breast cancer cells that
overexpress HER2
From the data presented above, trastuzumab treatment
increases miR-194 (Tables 1 & 2 and Fig. 1) and miR-194
negatively regulates cell migration (Fig. 2) and talin2 expression
(Fig. 3). To determine whether trastuzumab downregulates talin2
expression, BT474, SKBr3 cells and BT474 xenograft tumors
were treated with trastuzumab or control hIgG and total protein
was collected, Western blots prepared and stained with anti-talin2.
As shown in Figure 4D, trastuzumab treatment decreased talin2
protein expression in a dose-dependent manner in BT474 cells.
Quantitation of talin2 protein levels after trastuzumab treatment
in three different experiments confirmed the dose-dependent effect
(Fig. 4E). Trastuzumab treatment also decreased talin2 protein in
SKBr3 cells (Fig. 4F). A similar downregulation of talin2 was
observed in BT474 xenografts growing in nude mice. Trastuzu-
mab inhibited talin2 protein expression (the lower band) in two
different tumors (Fig. 4G). Trastuzumab treatment also produced
a decrease in total Rb protein in BT474 xenografts, consistent with
activity of the antibody in vivo [15].
Knockdown of miR-194 promotes cancer cell migration
and reverses trastuzumab inhibition of cell migration
To determine whether a decrease in miR-194 would increase
motility, SKBr3 cells were transiently transfected with a specific
miR-194 inhibitor or antagomir. As shown in Figure 5A,
transfection of SKBr3 cells with a miR-194 antagomir increased
Figure 3. miR-194 targets the talin2 gene and downregulates talin2 protein levels. (A) Alignment of miR-194 with talin2 (TLN2) 39-UTRs.
Complementary sequences of miR-194 and mammalian talin2 39-UTRs are marked in Bold. The seed sequences of miR-194 are underlined. Has,
human; Ptr, pan troglotydes; Mmu, mus musculus; Rno, rat; Ocu, rabbit; Eeu, hedgehog; Cfa, dog; Fca, cat; Eca, horse; Laf, elephant. The underlined
seed nucleotides were deleted in the talin2 39-UTR mutant reporter construct described in (B). (B) Effect of miR-194 expression on the luciferase
activities of wild-type and mutated talin2 39-UTR reporters. MDA-MB-361 cells were transiently transfected with a miR Control or miR-194 precursor
for 36 hrs. Luciferase activity was determined using a dual luciferase assay. ** p,0.01. (C) Effect of miR-194 expression on talin2 protein levels in
SKBr3 cells. SKBr3 cells were transiently transfected with a miR-194 precursor or a control miRNA (miR CTRL) for 48 hrs. Total protein was prepared
and subjected to Western blotting. (D) Effect of talin2 downregulation on cell migration in SKBr3 cells. SKBr3 cells were transiently transfected with
two siTalin2 (siTLN2 #7 and #8) or its control siRNA (siCTRL) for 48 hrs and then motility was measured overnight in a Transwell assay. * p,0.05
compared to siCTRL. (E) Effect of talin2 downregulation on cell invasion. SKBr3 cells were transiently transfected with two siTalin2 (siTLN2#7 and#8)
or its control siRNA (siCTRL) for 48 hrs and then invasion assay was performed. * p,0.05 compared to siCTRL. (F) Validation of talin2 siRNA efficacy.
SKBr3 cells were transiently transfected with two siTalin2 (siTLN2 #7 and #8) or its control siRNA (siCTRL) or the transfection reagent only (mock) for
48 hrs and total protein was prepared. Western blotting was performed with a talin2 antibody.
doi:10.1371/journal.pone.0041170.g003
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cancer cell migration by more than 55%. The ability of the miR-
194 antagomir to silence miR-194 was confirmed by QRT-PCR
as shown in Figure 5B. Similar results were observed in BT474
cells, where inhibition of miR-194 by a miR-194 antagomir
stimulated BT474 cell migration (Fig. 5C). Consistent with the
results of in vitro scratch assay, trastuzumab treatment decreased
the BT474 cell migration (Fig. 5C). However, trastuzumab
treatment was no longer able to inhibit cell migration in the
presence of miR-194 antagomir or inhibitor (Fig. 5C), indicating
miR-194 induction was required for trastuzumab to slow cell
migration in breast cancer cells.
Figure 4. Trastuzumab treatment downregulates talin2 protein expression and inhibits breast cancer cell migration. (A) Effect of
trastuzumab (Tras) on cell migration in a scratch assay. BT474 and SKBr3 cells were seeded in 6-well plates. After cells had grown to confluence, a
scratch was made in the monolayer. Cells were treated with trastuzumab (Tras) or control hIgG (10 mg/ml) for 72 hrs. Images were recorded at 72 hrs
at 406 enlargement. (B) Effect of trastuzumab on cell migration over a shorter interval (16 h) in a scratch assay. SKBr3 cells were seeded in 6-well
culture plates and cultured overnight to achieve a cell density of full confluence. A scratch was made in the monolayer. Cells were then treated with
trastuzumab (Tras) or control hIgG (10 mg/ml) plus epidermal growth factor (EGF, 20 ng/ml, sigma) for 16 hrs. Images were recorded at the end of
16 hrs of EGF stimulation at 406enlargement. (C) Effect of trastuzumab (Tras) on cytoskeletal vinculin distribution after IF staining. SKBr3 cells were
treated with trastuzumab (Tras) or control hIgG (10 mg/ml) for 48 hrs, and then subjected to IF staining as described in Methods. (D) Effect of
trastuzumab on talin2 protein in BT474 cells. BT474 cells were treated in vitro with different concentrations of trastuzumab for 48 hrs. Total protein
was prepared and subjected to Western blotting. (E) Quantitation of talin2 expression. The talin2 bands on immunoblots from three different
experiments including the one shown in (D) were digitized, normalized to the levels of GAPDH, and expressed as mean levels (error bars correspond
stand deviation). The talin2 expression at trastuzumab 0 concentration was set at 1. (F) Effect of trastuzumab on talin2 protein in SKBr3 cells. SKBr3
cells were treated with trastuzumab (Tras) or control hIgG (10 mg/ml) for 48 hrs. Total protein was prepared and subjected to Western blotting. (G)
Effect of trastuzumab on talin2 protein in BT474 xenografts. BT474 xenografts in nude mice were treated with trastuzumab (Tras) or hIgG 1 mg/kg
intraperitoneally twice a week and for 3 weeks. Total cell lysates were prepared and subjected to Western blotting.
doi:10.1371/journal.pone.0041170.g004
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Discussion
In this study, we have found for the first time that miR-194 is
induced in HER2-overexpressing breast cancer cells by trastuzu-
mab treatment. Forced expression of miR-194 inhibits cell
migration and decreases levels of talin2, a cytoskeletal protein.
Treatment with trastuzumab also inhibits breast cancer cell
migration and decreases talin2 expression. Depletion of miR-194
stimulates breast cancer cell migration and abolishes trastuzumab-
inhibited cell migration.
The regulatory role of miR-194 was first studied in normal and
malignant cells of the gastrointestinal tract. High levels of miR-194
are expressed in the intestines and liver [50,51]. Hepatocyte
nuclear factor (HNF) can induce miR-194 expression during
intestinal epithelial cell differentiation [52,53]. miR-194 suppresses
invasion and migration of liver mesenchymal-like cancer cells [54].
miR-194 expression is elevated in normal colon tissues and low in
colon cancers [55]. Low miR-194 expression has been associated
with large tumor size and advanced stage in gastric cancer [56].
Activation of tumor suppressor p53 can induce miR-194 and its
clustered miR-192 and miR-215 expression [55,57]. miR-192 and
miR-215 can induce p21Cip1 and cell cycle arrest in colon cancer
cells [55]. In endometrial cancer cells, miR-194 has been reported
to inhibit self-renewal factor BMI-1, reduce cell invasion and
inhibit epithelial-mesenchymal transition (EMT) [58]. While
inhibition of cell migration by miR-194 has been demonstrated
in other systems, this is the first report to show that miR-194 can
inhibit breast cancer cell migration (Fig. 2) and that miR-194 and
migration can be regulated by trastuzumab.
Our data suggest that miR-194-induced inhibition of motility is
mediated by downregulation of cytoskeletal proteins. We have
demonstrated for the first time that miR-194 inhibits talin2 protein
expression and binds to the talin2 39-UTR (Fig. 3). In addition to
regulating talin2, we have also observed that miR-194 expression
reduces profilin2, another cytoskeletal protein (data not shown).
However, miR-194 did not bind directly to the profilin2 39-UTR
in a luciferase reporter assay. miR-194 has been shown by others
to target migration-related proteins including N-cadherin, Rac1,
heparin-binding epidermal growth factor–like growth factor, type
1 insulin-like growth factor receptor, protein tyrosine phosphatase-
non receptor type 12, integrin-alpha 9, suppressor of cytokine
signaling 2, and BMI1 polycomb ring finger oncogene [54,56,58].
Inhibition of these other cytoskeletal and migration-related
proteins may contribute to miR-194-induced inhibition of cell
migration/invasion as well.
Talin1 and talin2 are actin-binding cytoskeletal proteins that
play key roles in cell signaling, adhesion, and migration
[48,49,59,60]. Both talin1proteins are closely coupled to vinculin,
another cytoskeletal protein found in focal adhesion complexes
[49]. Both talin1 and talin2 (74% identity) can bind to integrins
and to F actin via FERM (four-point-one, ezrin, radixin, moesin)
domains and are important regulators of integrin activation
[59,60,61,62]. Genetic knockout of talin1 alone does not affect
fibroblast spreading due to the compensatory activity of talin2, but
does impair cytoskeletal organization [63]. Double deletion of
talin1 and talin2 abolishes extracellular matrix–cytoskeletal linkage
through integrins and blocks assembly of focal adhesions [64].
Talin1 knockdown in the absence of talin2 compensation has been
shown to prevent spreading of endothelial cells and block
angiogenesis leading to embryonic death [65]. Forced expression
of talin1 enhances migration and invasion of prostate cancer cells
[66]. Talin1 overexpression is a poor prognostic factor in prostate
[66], liver [67] and oral [68] cancers. The role of talin2 in cancer
cells including in breast cancer has not yet been reported. This
study indicates that suppression of talin2 can inhibit breast cancer
cell migration.
Trastuzumab treatment seems to exert its anti-tumor effect
through multiple mechanisms including inducing miRNAs. After
completing this study, one report has been just published and
shown that trastuzumab treatment can induce miR-26a and miR-
30b, leading to inhibition of cylcin E2 expression and G1 arrest of
the cell cycle [69]. Our study has identified another miRNA (miR-
194) and new target (talin 2, motility) in HER2-overexpressing
breast cancer cells.
In conclusion, our study describes a novel mechanism of
trastuzumab action in breast cancer cells. Treatment with
trastuzumab can activate miR-194 expression, downregulate
Figure 5. miR-194 inhibitor stimulates cell migration and blocks trastuzumab-inhibited cell migration. (A) Effect of miR-194 inhibitor on
cell migration in SKBr3 cells. SKBr3 cells were transiently transfected with a miR-194 inhibitor or its negative control (miR inhibitor CTRL) for 48 hrs
before measurement of migration overnight. * p,0.05 compared to the negative control. (B) Validation of efficacy of miR-194 inhibition. SKBr3 cells
were transiently transfected with a miR-194 inhibitor or its negative control (miR inhibitor CTRL) for 48 hrs. Total RNA was prepared and miR-194
measured by QRT-PCR. * p,0.05 compared to miR inhibitor control. (C) Effect of miR-194 inhibitor on trastuzumab-inhibited cell migration. SKBr3
cells were transiently transfected with a miR-194 inhibitor or its negative control (miR inhibitor CTRL) for 16 hrs, treated with trastuzumab (Tras) or
control hIgG (10 mg/ml) for 36 hrs, and motility was then measured for overnight in Transwell assays. * p,0.05.
doi:10.1371/journal.pone.0041170.g005
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cytoskeletal protein talin2 expression and inhibit cell migration/
invasion in HER2-overexpressing breast cancer cells.
Supporting Information
Figure S1 Heatmap of the differentially expressed
miRNAs in response to trastuzumab treatment in
HER2-overexpressing SKBr3 cells (A) and BT474 cells
(B). To visualize the clusters of expressed miRNAs after
trastuzumab treatment, hierarchical clustering was performed
based on the differentially expressed miRNAs. Names of samples
(top) and miRNAs (side) is shown by using One Minus Correlation
as a distance measure after genes centering and scaling, and
average linkage method for defining the distance between the
clusters. Sample BRC20, SKBr3 cells treated control hIgG for
20 hrs; BRHCT20, SKBr3 cells treated trastuzumab for 20 hrs;
BTC48, BT474 cells treated with control hIgG for 48 hrs;
BTHCT48, BT474 cells treated with trastuzumab for 48 hrs. A
color scale of expression is shown between panel A and B.
(TIF)
Figure S2 Effects of trastuzumab on miR-194 expres-
sion in the MDA-MB-231 cells with low-HER2 level and
the KPL4 cells with high-HER2 level. Two trastuzumab-
insensitive breast cancer cell lines MDA-MB-231 (A) and KPL4
(B) were treated with trastuzumab (Tras) at different concentra-
tions (0, 5, 10 mg/ml) for 48 hrs. Total RNA was prepared and
analyzed by QRT-PCR in triplicate for miR-194 levels.
(TIF)
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